Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension

Clinical Therapeutics

Volumn 19, Issue 6, 1997, Pages 1368-1378

  Karch, Fred E ^a   Pordy, Robert ^a   Benz, Joan Ryder ^a   Carr, Albert ^a   Lunde, N Martin ^a   Marbury, Thomas ^a   Tarro, James N ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Amlodipine; Hypertension; Leg edema; Mibefradil

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; MIBEFRADIL;

ADULT; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SITTING; TREATMENT OUTCOME;

EID: 0031408941     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80011-2     Document Type: Article

References (34)

1. Oparil S, Calhoun D. The calcium antagonists in the 1990s: An overview. Am J Hypertens. 1991;4:396S-405S.
2. Messerli F. Case-control study, metaanalysis, and bouillabaisse: Putting the calcium antagonist scare into context. Ann Intern Med. 1995;123:888-889.
3. Mehta J, Lopez L, Vlachakis N, et al. Double-blind evaluation of the dose-response relationship of amlodipine in essential hypertension. Am Heart J. 1993; 125:1704-1710.
4. Frick M, McGibney D, Tyler H. Amlodipine: A double-blind evaluation of the dose-response relationship in mild to moderate hypertension. J Candiovasc Pharmacol. 1988;12(Suppl 7):S76-S78.
5. Mroczek W, Barris J, Allenby K. A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure in hypertensive patients. J Cardiovasc Pharmacol. 1988;12(Suppl 7):S79-S84.
6. Detry J-M, Block P, DeBacker G, et al. Patient compliance and therapeutic coverage: Comparison of amlodipine and slow release nifedipine in the treatment of hypertension. Eur J Clin Pharmacol. 1995; 47:477-481.
7. O'Connor C, Belkin R, Carson P, et al. Effect of amlodipine on mode of death in severe chronic heart failure: The PRAISE trial. Circulation. 1995;92:I-143. Abstract.
8. Furberg C, Psaty B, Meyer J. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331.
9. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol. 1991;67:1295-1297.
10. 2+ channel in cardiac tissue. Eur J Pharmacol. 1995;290:155-158.
11. 2+ channels by Ro 40-5967. Circ Res. 1994;75:144-148.
12. Schmitt R, Kleinbloesem C, Belz G, et al. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther. 1992;52:314-323.
13. Rousseau M, Hayashida W, van Eyll C, et al. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocker, mibefradil, in patients with varying degrees of left ventricular systolic dysfunction. J Am Coll Cardiol. 1996;28:972-979.
14. Ezzaher A, Bouanani N, Su J, et al. Increased negative inotropic effect of calcium channel blockers in hypertrophied and failing rabbit heart. J Pharmacol Exp Ther. 1991;257:466-471.
15. 3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther. 1990;4:731-736.
16. Clozel J-P, Osterrieder W, Kleinbloesem C, et al. Ro 40-5967: A new non-dihydropyridine calcium antagonist. Cardiovasc Drug Rev. 1991;9:4-17.
17. Bernink P, Prager G, Schelling A, Kobrin I. Antihypertensive properties of the novel calcium antagonist mibefradil (RO 40-5967): A new generation of calcium antagonists? Hypertension. 1996;27:426-432.
18. Bakx A, van der Wall E, Braun S, et al. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study. Am Heart J. 1995;130:748-757.
19. Viskoper R, Bernink P, Schelling A, et al. A randomized, double-blind trial comparing mibefradil and amlodipine: Two long-acting calcium antagonists with similar efficacy but different tolerability profiles. J Hum Hypertens. 1997;11:459-466.
20. Westlake W. Symmetrical confidence intervals for bioequivalence trials. Biometrics. 1976;32:741-744.
21. Gillum R, Makuc D, Feldman J. Pulse rate, coronary heart disease, and death: The NHANES I epidemiologic follow-up study. Am Heart J. 1991;121:172-177.
22. Thaulow E, Erikssen J. How important is heart rate? J Hypertens. 1991;9:527-530.
23. Dyer A, Persky V, Stamler J, et al. Heart rate as a prognostic factor for coronary heart disease and mortality: Findings in three Chicago epidemiologic studies. Am J Epidemiol 1980;112:736-749.
24. Perski A, Ollson G, Landou C, et al. Minimum heart rate and coronary atherosclerosis: Independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J. 1992;123:609-616.
25. Kannel W, Kannel C, Paffenbarger R. Cupples A. Heart rate and cardiovascular mortality: The Framingham Study. Am Heart J. 1987;113:1489-1494.
26. Jamerson K, DeQuattro V. The impact of ethnicity on response to antihypertensive therapy. Am J Med. 1996;101(Suppl 3A): 22S-32S.
27. Materson B, Reda D, Cushman W, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. NEJM. 1993; 328:914-921.
28. Wright JT, Douglas JG. Drug therapy in the black hypertensive. In: Douglas JG, Fray JC, eds. Pathophysiology of Hypertension in Blacks. New York: Oxford University Press, 1993.
29. Zing WR, Ferguson RK, Vlasses PH. Calcium antagonists in elderly and black hypertensive patients: Therapeutic controversies. Arch Intern Med. 1991;151: 2154-2162.
30. Moser M. Implications of recent clinical trials in systemic hypertension. II: Results of a multicenter trial of nitrendipine, for mild to moderately severe systemic hypertension. Am J Cardiol. 1986;58(Suppl): 23D-26D.
31. Moser M, Lunn J, Nash D, et al. Nitrendipine in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol. 1984;6(Suppl 10):S85-S86.
32. Halpern A, Gross K, Rogers J, Cubeddu L. Verapamil and propranolol in essential hypertension. Clin Pharmacol Ther. 1984; 36:750-758.
33. Cubeddu LX, Aranda J, Singh B, et al. A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response. JAMA. 1986;256:2214-2221.
34. Gillum RF, Grant CT. Coronary heart disease in black populations: II. Risk factors. Am Heart J. 1982;104:852-864.